WebSpotlight Therapeutics has raised $30 million in series A financing to develop CRISPR gene-editing therapies for genetic blood diseases and cancer. Spotlight attaches antibodies, cell-penetrating peptides, or ligands to a CRISPR ribonucleoprotein—a guide RNA paired with a nuclease like Cas9—to shuttle the gene-editing system to particular ... Web5 Nov 2024 · We found that 18% of the patients had post-CAR HCT as a consolidation therapy with a favorable safety profile of 8.9% TRM rate despite a prior transplant rate of 36%. Consolidation HCT after CAR T cell resulted in significant reduction in leukemia relapse with a trend towards better DFS.

Scientific Advisory Board — Spotlight Therapeutics

Web5 Jan 2024 · Spotlight Therapeutics's latest funding round was a Series B for $36.5M on January 5, 2024. Date. Round. Amount. Investors. Valuation. Valuations are submitted by … WebSpotlight Therapeutics. Produced by. While CRISPR-based therapeutics are showing proof-of-concept in the clinic, in vivo gene editing with cell-type specificity remains a major … rothiemurchus camping caravan park

Spotlight Therapeutics - Funding, Financials, Valuation & Investors

WebBack to Top. Spotlight Therapeutics, 3953 Point Eden Way, Hayward, CA 94545 emailemail WebWe invest in innovative founders across industries and optimize for ideas that demand long-term relationships — ones where we can provide value across multiple stages and milestones. WebSpotlight has established a discovery engine for pooled screening of thousands of bar-coded TAGE variants on primary cells and identified multiple CPPs that confer cell penetration and nuclear... st philips catholic school arundel